84145-72-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyanopentylmorpholine is used as a building block for the synthesis of various drugs and pharmaceuticals, contributing to the development of new medications and therapies.
Used in Agrochemical Production:
4-cyanopentylmorpholine is utilized as an intermediate in the production of agrochemicals, playing a role in the creation of products that protect and enhance crop yields.
Used as a Solvent:
4-Cyanopentylmorpholine is used as a solvent in organic synthesis, facilitating chemical reactions and aiding in the production of various organic compounds.
Used as a Chemical Reagent:
In organic synthesis, 4-cyanopentylmorpholine serves as a chemical reagent, enabling specific chemical transformations and the synthesis of target molecules.

InChI:InChI=1/C9H16N2O/c10-4-2-1-3-5-11-6-8-12-9-7-11/h1-3,5-9H2

Upstream product

• 2180-69-0 (Z)-2,4-pentadienenitrile 
• 110-91-8 morpholine 
• 6280-87-1 δ-chlorovaleronitrile 

Downstream Products

• 929257-57-8 4-morpholinobutyl 2-(3-(trifluoromethyl)phenylamino)pyridine-3-carboxylate 
• 39793-32-3 5-morpholino-pentylamine 

Relevant academic research and scientific papers

Solid state and solution study on the formation of inorganic anion complexes with a series of tetrazine-based ligands

Four molecules (L1–L4) constituted by an s-tetrazine ring appended with two identical aliphatic chains of increasing length bearing terminal morpholine groups were studied as anion receptors in water. The basicity properties of these molecules were also investigated. Speciation of the anion complexes formed in solution and determination of their stability constants were performed by means of potentiometric (pH-metric) titrations, while further information was obtained by NMR and isothermal titration calorimetry (ITC) measurements. The crystal structures of two neutral ligands (L3, L4) and of their H2L3(ClO4)2·2H2O, H2L4(ClO4)2·2H2O, H2L3(PF6)2, and H2L3(PF6)2·2H2O anion complexes were determined by single crystal X-ray diffraction. The formation of anion–π interactions is the leitmotiv of these complexes, both in solution and in the solid state, although hydrogen bonding and/or formation of salt-bridges can contribute to their stability. Evidence of the ability of these ligands to form anion–π interactions is given by the observation that even the neutral (not-protonated) molecules bind anions in water to form complexes of significant stability, including elusive OH? anions.

A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor

Recently, a novel negative allosteric modulator (NAM) of the D2-like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.

BENZYL SUBSTITUTED INDAZOLES

Compounds of formula (I) and their use as pharmaceuticals.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.